Analyst Research Roundup: Rocket Pharmaceuticals, Inc. (RCKT), Nanometrics Incorporated (NANO)

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) tinted loss of -0.97% (-0.15 points) to US$15.28. The volume of 0.1 Million shares climbed down over an trading activity of 291.73 Million shares. EPS ratio determined by looking at last 12 month figures is -1.94. Over the same time span, the stock marked US$25.96 as its best level and the lowest price reached was US$10.75. The corporation has a market cap of US$646.65 Million.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)’s earnings per share has been growing at a -16.2 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -46.8 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 86.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.33. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Nanometrics Incorporated (NASDAQ:NANO) is worth US$718.92 Million and has recently risen 1.8% to US$29.93. The latest exchange of 0.14 Million shares is below its average trading activity of 193.84 Million shares. The day began at US$29.72 but the price moved to US$29.6 at one point during the trading and finally capitulating to a session high of US$30.23. The stock tapped a 52-week high of US$48.26 while the mean 12-month price target for the shares is US$37.67.

Currently, the stock carries a price to earnings ratio of 12.7, a price to book ratio of 2.45, and a price to sales ratio of 2.22. For the past 5 years, the company’s revenue has grown 7.2%, while the company’s earnings per share has grown 46.8%. With an institutional ownership near 87.5%, it carries an earnings per share ratio of 2.36.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.